Xintong Medical-B (02160) announced that VitaFlow Liberty, independently developed by the group...
Zhitong Finance App News, Xintong Medical-B (02160) issued an announcement. VitaFlow Liberty independently developed by the GroupTranscatheter aortic valve and recyclable delivery system (VitaFlow Liberty) The CE mark (certification mark indicating that products sold within the European Economic Area meet health, safety and environmental standards) was approved on April 24, 2024.
VitaFlow LibertyIt is a second-generation transcatheter aortic valve implantation product independently developed by the group. Up to now, VitaFlow LibertyThe surgical accessories used in conjunction with it have entered nearly 600 hospitals in China, and have entered nearly 100 hospitals in Argentina, Colombia, Thailand, Russia and Indonesia.
VitaFlow LibertyThe CE mark approval means that its innovative R&D design and excellent clinical performance have reached the international level. It is a critical milestone in the company's development process and global strategic layout. It provides a prerequisite for the Group to enter the European structural cardiac interventional treatment market. It will further expand the Group's sales revenue sources, enhance its comprehensive competitiveness, provide more global doctors and patients with inclusive, true, and beautiful medical solutions from China, and help promote innovation and development in the field of global heart valve intervention.